Physician profile
Jared Galloway
NPI 1114487758
$3,934.34
in general payments reported to CMS, 2019-2025
29 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $417 · 2023: $1,268 · 2024: $614 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $506.67 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $414.56 | 2023-2025 | |
| Lilly USA, LLC | $365.82 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $365.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $315.17 | 2022-2025 | |
| Glaxosmithkline, LLC. | $299.29 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.01 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $127.65 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $112.22 | 2022-2023 | Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.72 | 2022-2025 | Jardiance |
| Philips North America LLC | $96.89 | 2024-2025 | (Ck7) Extended Holter, Extended Holter |
| Dexcom, INC. | $86.60 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $70.00 | 2022-2024 | Gvoke Hypopen |
| Lundbeck LLC | $56.89 | 2023-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.65 | 2023-2024 | Repatha, Otezla |
| Gilead Sciences, INC. | $45.02 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $32.89 | 2023 | Rexulti |
| Abiomed | $24.90 | 2025 | |
| Astellas Pharma US INC | $19.37 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $17.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2022 | |
| Shield Therapeutics INC | $16.44 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.00 | 2025 | Qelbree |
| Corcept Therapeutics | $15.62 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $14.68 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $12.15 | 2022 | |
| Dynavax Technologies Corporation | $10.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.